PROCHLORPERAZINE


DrugBank ID: db00433
DrugCentral: prochlorperazine
Synonymous :2-chloro-10-(3-(1-methyl-4-piperazinyl)propyl)-phenothiazine | 2-chloro-10-(3-(4-methyl-1-piperazinyl)propyl)phenothiazine | 3-chloro-10-(3-(1-methyl-4-piperazinyl)propyl)phenothiazine | 3-chloro-10-(3-(4-methyl-1-piperazinyl)propyl)phenothiazine | capazine | chlormeprazine | chloro-3 (n-methylpiperazinyl-3 propyl)-10 phenothiazine | chloropernazine | n-(gamma-(4’-methylpiperazinyl-1’)propyl)-3-chlorophenothiazine | prochlorperazin | prochlorpérazine | prochlorperazine | prochlorperazinum | prochlorpermazine | prochlorpromazine | procloperazine | proclorperazina



Drug Sentece Context


Table 1. Analysis of context sentence of prochlorperazine gene in 3 abstracts.

pmid sentence
32616067 To be included in the trial the participant MUST: 1) Have given written informed consent to participate 2) Be aged 18 years to 70 years 3) Not previously have been diagnosed with COVID-19 4) Work in a high-risk secondary or tertiary healthcare setting (hospitals accepting COVID-19 patients) with direct patient-facing care EXCLUSION CRITERIA: The presence of any of the following will mean participants are ineligible: 1) Known COVID-19 positive test at baseline (if available) 2) Symptomatic for possible COVID-19 at baseline 3) Known hypersensitivity reaction to hydroxychloroquine, chloroquine or 4-aminoquinolines 4) Known retinal disease 5) Known porphyria 6) Known chronic kidney disease (CKD; eGFR<30ml/min) 7) Known epilepsy 8) Known heart failure or conduction problems 9) Known significant liver disease (Gilbert’s syndrome is permitted) 10) Known glucose-6-phosphate dehydrogenase (G6PD) deficiency 11) Currently taking any of the following contraindicated medications: Digoxin, Chloroquine, Halofantrine, Amiodarone, Moxifloxacin, Cyclosporin, Mefloquine, Praziquantel, Ciprofloxacin, Clarithromycin, Prochlorperazine, Fluconazole 12) Currently taking hydroxychloroquine or having a clinical indication for taking hydroxychloroquine 13) Currently breastfeeding 14) Unable to be followed-up during the trial 15) Current or future involvement in the active treatment phase of other interventional research studies (excluding observational/non-interventional studies) before study follow-up visit 16) Not able to use or have access to a modern phone device/web-based technology 17) Any other clinical reason which may preclude entry in the opinion of the investigator INTERVENTION AND COMPARATOR: Interventions being evaluated are: A) Daily hydroxychloroquine or B) Weekly hydroxychloroquine or C) Placebo The maximum treatment period is approximately 13 weeks per participant.
32949606 The goal of this paper was to summarize the current literature on activity toward RNA-viruses of such drugs like chlorpromazine, fluphenazine, perphenazine, prochlorperazine, and thioridazine. […] Chlorpromazine, fluphenazine, perphenazine, prochlorperazine, and thioridazine possess anti-viral activity towards different types of viruses.